Literature DB >> 26836186

Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.

Pratishtha Chatterjee1,2,3,4, Wei L F Lim2,3,4, Guanghou Shui5, Veer B Gupta2,3,4, Ian James6, Anne M Fagan7,8, Chengjie Xiong8,9, Hamid R Sohrabi1,2,3,4, Kevin Taddei1,2,4, Belinda M Brown1,2,4, Tammie Benzinger8,10, Colin Masters11, Stuart G Snowden12, Marcus R Wenk13, Randall J Bateman7,8, John C Morris7,8, Ralph N Martins1,2,3,4.   

Abstract

BACKGROUND AND
OBJECTIVE: Aberrant lipid metabolism has been implicated in sporadic Alzheimer's disease (AD). The current study investigated plasma phospholipid and sphingolipid profiles in individuals carrying PSEN1 mutations responsible for autosomal dominant AD (ADAD).
METHODS: Study participants evaluated were from the Perth and Melbourne sites of the Dominantly Inherited Alzheimer Network (DIAN) study. Plasma phospholipid and sphingolipid profiles were measured using liquid chromatography coupled with mass spectrometry in 20 PSEN1 mutation carriers (MC; eight of whom were symptomatic and twelve asymptomatic, based on Clinical Dementia Rating scores) and compared with six non carriers (NC) using linear mixed models. Further, AD gold standard biomarker data obtained from the DIAN database were correlated with lipid species significantly altered between MC and NC, using Spearman's correlation coefficient.
RESULTS: One-hundred and thirty-nine plasma phospholipid and sphingolipid species were measured. Significantly altered species in MC compared to NC primarily belonged to choline and ethanolamine containing phospholipid classes and ceramides. Further phosphatidylcholine species (34:6, 36:5, 40:6) correlated with cerebrospinal fluid tau (p <  0.05), and plasmalogen ethanolamine species (34:2, 36:,4) correlated with both cerebrospinal fluid tau and brain amyloid load within the MC group (p <  0.05).
CONCLUSION: These findings indicate altered phospholipid and sphingolipid metabolism in ADAD and provide insight into the pathomolecular changes occurring with ADAD pathogenesis. Further, findings reported in this study allow comparison of lipid alterations in ADAD with those reported previously in sporadic AD. The findings observed in the current pilot study warrant validation in the larger DIAN cohort.

Entities:  

Keywords:  Alzheimer’s disease; biomarkers; familial Alzheimer’s disease; phospholipids; sphingolipids

Mesh:

Substances:

Year:  2016        PMID: 26836186      PMCID: PMC4943576          DOI: 10.3233/JAD-150948

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

1.  Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry.

Authors:  X Han; D M Holtzman; D W McKeel
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

Review 2.  Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.

Authors:  Xianlin Han; Richard W Gross
Journal:  Mass Spectrom Rev       Date:  2005 May-Jun       Impact factor: 10.946

Review 3.  Lipids and the pathogenesis of Alzheimer's disease: is there a link?

Authors:  Michelle M Mielke; C G Lyketsos
Journal:  Int Rev Psychiatry       Date:  2006-04

4.  Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss.

Authors:  Michelle M Mielke; Norman J Haughey; Veera Venkata Ratnam Bandaru; Steven Schech; Richard Carrick; Michelle C Carlson; Susumu Mori; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

5.  Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism.

Authors:  Natalie Landman; Soon Youn Jeong; Sun Young Shin; Sergey V Voronov; Geo Serban; Min Suk Kang; Myung Kyu Park; Gilbert Di Paolo; Sungkwon Chung; Tae-Wan Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-08       Impact factor: 11.205

6.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.

Authors:  Marcus O W Grimm; Heike S Grimm; Andreas J Pätzold; Eva G Zinser; Riikka Halonen; Marco Duering; Jakob A Tschäpe; Bart De Strooper; Ulrike Müller; Jie Shen; Tobias Hartmann
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

7.  Serum sphingomyelins and ceramides are early predictors of memory impairment.

Authors:  Michelle M Mielke; Veera Venkata Ratnam Bandaru; Norman J Haughey; Peter V Rabins; Constantine G Lyketsos; Michelle C Carlson
Journal:  Neurobiol Aging       Date:  2008-05-05       Impact factor: 4.673

8.  Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.

Authors:  Alfred N Fonteh; Jiarong Chiang; Matthew Cipolla; Jack Hale; Fatimatou Diallo; Alejandra Chirino; Xianghong Arakaki; Michael G Harrington
Journal:  J Lipid Res       Date:  2013-07-18       Impact factor: 5.922

Review 9.  Arachidonic acid as a neurotoxic and neurotrophic substance.

Authors:  H Katsuki; S Okuda
Journal:  Prog Neurobiol       Date:  1995-08       Impact factor: 11.685

Review 10.  Docosahexaenoic acid: membrane properties of a unique fatty acid.

Authors:  William Stillwell; Stephen R Wassall
Journal:  Chem Phys Lipids       Date:  2003-11       Impact factor: 3.329

View more
  13 in total

Review 1.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

2.  The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging.

Authors:  Michelle M Mielke; Norman J Haughey; Dingfen Han; Yang An; Veera Venkata Ratnam Bandaru; Constantine G Lyketsos; Luigi Ferrucci; Susan M Resnick
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease.

Authors:  Kathryn Goozee; Pratishtha Chatterjee; Ian James; Kaikai Shen; Hamid R Sohrabi; Prita R Asih; Preeti Dave; Bethany Ball; Candice ManYan; Kevin Taddei; Roger Chung; Manohar L Garg; Ralph N Martins
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

Review 4.  Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.

Authors:  Ralph N Martins; Victor Villemagne; Hamid R Sohrabi; Pratishtha Chatterjee; Tejal M Shah; Giuseppe Verdile; Paul Fraser; Kevin Taddei; Veer B Gupta; Stephanie R Rainey-Smith; Eugene Hone; Steve Pedrini; Wei Ling Lim; Ian Martins; Shaun Frost; Sunil Gupta; Sid O'Bryant; Alan Rembach; David Ames; Kathryn Ellis; Stephanie J Fuller; Belinda Brown; Samantha L Gardener; Binosha Fernando; Prashant Bharadwaj; Samantha Burnham; Simon M Laws; Anna M Barron; Kathryn Goozee; Eka J Wahjoepramono; Prita R Asih; James D Doecke; Olivier Salvado; Ashley I Bush; Christopher C Rowe; Samuel E Gandy; Colin L Masters
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease.

Authors:  Wei Ling Florence Lim; Kevin Huynh; Pratishtha Chatterjee; Ian Martins; Kaushala S Jayawardana; Corey Giles; Natalie A Mellett; Simon M Laws; Ashley I Bush; Christopher C Rowe; Victor L Villemagne; David Ames; Brian G Drew; Colin L Masters; Peter J Meikle; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 6.  Blood-based molecular biomarkers for Alzheimer's disease.

Authors:  Henrik Zetterberg; Samantha C Burnham
Journal:  Mol Brain       Date:  2019-03-28       Impact factor: 4.041

7.  Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimer's Disease Mimic Accelerated Aging.

Authors:  Fabian Dorninger; Ann B Moser; Jianqiu Kou; Christoph Wiesinger; Sonja Forss-Petter; Andreas Gleiss; Margareta Hinterberger; Susanne Jungwirth; Peter Fischer; Johannes Berger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  Comparison of Single Phase and Biphasic Extraction Protocols for Lipidomic Studies Using Human Plasma.

Authors:  Matthew Wai Kin Wong; Nady Braidy; Russell Pickford; Perminder Singh Sachdev; Anne Poljak
Journal:  Front Neurol       Date:  2019-08-21       Impact factor: 4.003

9.  Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease.

Authors:  Kevin Huynh; Wei Ling Florence Lim; Corey Giles; Kaushala S Jayawardana; Agus Salim; Natalie A Mellett; Adam Alexander T Smith; Gavriel Olshansky; Brian G Drew; Pratishtha Chatterjee; Ian Martins; Simon M Laws; Ashley I Bush; Christopher C Rowe; Victor L Villemagne; David Ames; Colin L Masters; Matthias Arnold; Kwangsik Nho; Andrew J Saykin; Rebecca Baillie; Xianlin Han; Rima Kaddurah-Daouk; Ralph N Martins; Peter J Meikle
Journal:  Nat Commun       Date:  2020-11-10       Impact factor: 14.919

10.  Association of Plasma Phospholipids with Age-Related Cognitive Impairment: Results from a Cross-Sectional Study.

Authors:  Ting-Ting Liu; Shao-Jie Pang; Shan-Shan Jia; Qing-Qing Man; Yu-Qian Li; Shuang Song; Jian Zhang
Journal:  Nutrients       Date:  2021-06-25       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.